ALTIMMUNE (ALT)
$5.58
0.01 (0.18%)
ALT Stock Quote Delayed 30 Minutes
The 3 Best Biotech Stocks to Buy in January 2024
Biotech is still one of the most exciting investments on the market, creating substantial opportunities for some of the best biotech stocks.
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
$5.59
Market Cap
428.97M
PE Ratio
-4.17
EPS
-1.3388
Volume (Avg. Vol.)
2.37M
Day's Range
$5.46 - $5.64
52-Week Range
$5.28 - $11.50
Dividend & Yield
N/A (N/A)
ALT Stock Predictions, Articles, and ALTIMMUNE News
Why Is Altimmune (ALT) Stock Down 67% Today?
Altimmune (ALT) stock is losing value on Tuesday after the company released results from a Phase 2 clinical trial for obesity.
Altimune (ALT) Stock Plummets 33% Despite Positive Clinical Data
Altimune (ALT) stock is falling hard on Wednesday even after reporting positive results from a Phase 1b clinical trial this morning.
ALT Stock: One Analyst Still Thinks Altimmune Prices Could Hit $34
Some clinical trial results released by Altimmune have shareholders rushing to sell. But, one analyst sees plenty of upside for ALT stock.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Good morning! We're taking a look at the biggest pre-market stock movers for Wednesday and that includes the winners and losers.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Get ready for another busy week of trading as we kick off Monday with a look at the biggest pre-market stock movers for today.
Altimmune Earnings: ALT Stock Rises 7% Despite Rough Q2 Results
Altimmune earnings from Tuesday evening have ALT stock higher despite the company reporting rough figures for second quarter of FY2020.
Altimmune Earnings: ALT Stock Tumbles 12% on FY Miss
Altimmune (ALT) earnings for the biopharmaceutical company's fiscal year of 2019 have ALT stock taking a dive Friday after missing estimates.
Altimmune Stock Has Major Pipeline Potential
There's no guarantee of a coronavirus cure, but Altimmune stock is worth owning on hopes of an effective vaccine.
Altimmune News: ALT Stock Rockets 110% on Coronavirus Vaccine News
Altimmune (ALT) news for Monday includes positive news about a vaccine to treat the coronavirus from China have ALT stock soaring higher.
Altimmune News: ALT Stock Skyrockets on Positive Flu Vaccine Data
Altimmune news concerning the results from a Phase 2 extension study of the company's NasoVAX has ALT stock heading higher today.
Why Altimmune Stock Is Sliding Lower Today
Altimmune stock was falling hard Monday on news that the company is selling additional stock to investors in a new offering.
Why Altimmune Stock Is Skyrocketing Today
Altimmune stock (ALT) soared more than 285% following successful clinical trial data of a medication and a reverse split of common shares.
